JP2013511540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511540A5 JP2013511540A5 JP2012540065A JP2012540065A JP2013511540A5 JP 2013511540 A5 JP2013511540 A5 JP 2013511540A5 JP 2012540065 A JP2012540065 A JP 2012540065A JP 2012540065 A JP2012540065 A JP 2012540065A JP 2013511540 A5 JP2013511540 A5 JP 2013511540A5
- Authority
- JP
- Japan
- Prior art keywords
- irinotecan
- glycine
- hydrogen halide
- salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004768 irinotecan Drugs 0.000 claims description 72
- 229910000039 hydrogen halide Inorganic materials 0.000 claims description 65
- 239000012433 hydrogen halide Substances 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 51
- 150000003839 salts Chemical group 0.000 claims description 47
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
- 239000004698 Polyethylene Substances 0.000 claims description 20
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 20
- 229920000573 polyethylene Polymers 0.000 claims description 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 229920002214 alkoxylated polymer Polymers 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- 238000004255 ion exchange chromatography Methods 0.000 claims description 4
- 239000002861 polymer material Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000004673 fluoride salts Chemical group 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26246309P | 2009-11-18 | 2009-11-18 | |
| US61/262,463 | 2009-11-18 | ||
| US29007209P | 2009-12-24 | 2009-12-24 | |
| US61/290,072 | 2009-12-24 | ||
| PCT/US2010/057292 WO2011063158A1 (en) | 2009-11-18 | 2010-11-18 | Salt form of a multi-arm polymer-drug conjugate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013511540A JP2013511540A (ja) | 2013-04-04 |
| JP2013511540A5 true JP2013511540A5 (https=) | 2013-11-21 |
| JP5901073B2 JP5901073B2 (ja) | 2016-04-06 |
Family
ID=43639124
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540065A Active JP5901073B2 (ja) | 2009-11-18 | 2010-11-18 | マルチアームポリマー−薬物コンジュゲートの塩形態 |
| JP2012540064A Active JP5951496B2 (ja) | 2009-11-18 | 2010-11-18 | ポリマー−薬物コンジュゲートの酸性塩形態及びアルコキシル化方法 |
| JP2015199074A Pending JP2016006127A (ja) | 2009-11-18 | 2015-10-07 | ポリマー−薬物コンジュゲートの酸性塩形態及びアルコキシル化方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540064A Active JP5951496B2 (ja) | 2009-11-18 | 2010-11-18 | ポリマー−薬物コンジュゲートの酸性塩形態及びアルコキシル化方法 |
| JP2015199074A Pending JP2016006127A (ja) | 2009-11-18 | 2015-10-07 | ポリマー−薬物コンジュゲートの酸性塩形態及びアルコキシル化方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US9226969B2 (https=) |
| EP (3) | EP2501413B1 (https=) |
| JP (3) | JP5901073B2 (https=) |
| KR (2) | KR101779229B1 (https=) |
| CN (2) | CN102711837B (https=) |
| AU (1) | AU2010321882B2 (https=) |
| BR (2) | BR112012011943A2 (https=) |
| CA (3) | CA2780779C (https=) |
| CY (1) | CY1121700T1 (https=) |
| DK (1) | DK2501413T3 (https=) |
| EA (2) | EA023503B1 (https=) |
| ES (2) | ES2723026T3 (https=) |
| HR (1) | HRP20191138T1 (https=) |
| HU (1) | HUE043689T2 (https=) |
| IL (2) | IL219866A (https=) |
| LT (1) | LT2501413T (https=) |
| ME (1) | ME03396B (https=) |
| MX (2) | MX338134B (https=) |
| PL (1) | PL2501413T3 (https=) |
| PT (1) | PT2501413T (https=) |
| RS (1) | RS58901B1 (https=) |
| SI (1) | SI2501413T1 (https=) |
| SM (1) | SMT201900294T1 (https=) |
| WO (2) | WO2011063158A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| ME03396B (me) | 2009-11-18 | 2020-01-20 | Nektar Therapeutics | Oblici kisele soli konjugata polimer-lek |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US20140378404A1 (en) * | 2011-10-25 | 2014-12-25 | Nektar Therapeutics | Treatment of Patients Suffering from Cancer |
| CN104662032A (zh) * | 2012-04-26 | 2015-05-27 | 阿米莱斯制药公司 | 用于体外减少β-淀粉样蛋白的新型组合物及其制备方法 |
| JP6300460B2 (ja) * | 2012-07-20 | 2018-03-28 | キヤノン株式会社 | 化合物、および前記化合物を有する光音響イメージング用造影剤 |
| WO2014036566A1 (en) * | 2012-08-31 | 2014-03-06 | Virginia Commonwealth University | Clickable polyoxetane carrier for drug delivery |
| CN104813167B (zh) | 2012-11-28 | 2019-04-09 | 尼克塔治疗公司 | 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法 |
| US9493766B2 (en) * | 2013-02-04 | 2016-11-15 | Corning Incorporated | PCR reaction cleanup buffers |
| EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| US9863949B2 (en) | 2013-05-31 | 2018-01-09 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents |
| CN104225611B (zh) * | 2013-06-18 | 2017-06-30 | 天津键凯科技有限公司 | 达沙替尼与非线性构型聚乙二醇的结合物 |
| EP3049114B1 (en) | 2013-09-27 | 2021-11-10 | Massachusetts Institute of Technology | Carrier-free biologically-active protein nanostructures |
| DK3052101T3 (da) * | 2013-10-04 | 2019-12-16 | Prolynx Llc | Konjugater af sn-38 med langsom frigivelse |
| JP5721806B2 (ja) * | 2013-10-04 | 2015-05-20 | Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 | 副作用のない抗癌剤 |
| EP3094331B1 (en) | 2014-01-14 | 2017-12-27 | Nektar Therapeutics | Combination-based treatment method |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| JP6542799B2 (ja) * | 2014-12-04 | 2019-07-10 | Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 | 新規ｐｅｇ誘導体 |
| US10548984B2 (en) * | 2015-02-04 | 2020-02-04 | United Arab Emirates University | RVG Derived peptides |
| CN108990413A (zh) | 2015-08-12 | 2018-12-11 | 麻省理工学院 | 纳米颗粒的细胞表面偶联 |
| CN107019803B (zh) * | 2016-01-29 | 2020-09-15 | 北京键凯科技股份有限公司 | 具有低成瘾作用的聚乙二醇化阿片样物质 |
| CN107375288B (zh) * | 2016-05-16 | 2019-08-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
| CN107469089B (zh) | 2016-06-07 | 2022-01-07 | 北京键凯科技股份有限公司 | 一种peg连接子及配基药物偶联物 |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス， インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| KR102619747B1 (ko) | 2017-01-10 | 2023-12-29 | 넥타르 테라퓨틱스 | Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법 |
| CN110235003B (zh) * | 2017-02-02 | 2022-04-01 | 阿尔卑斯阿尔派株式会社 | 平衡式电流传感器 |
| CN108727584B (zh) * | 2017-04-21 | 2021-01-05 | 博瑞生物医药（苏州）股份有限公司 | 抗癌偶联物 |
| EP3613792B1 (en) | 2017-04-21 | 2021-02-24 | Bright Gene Bio-Medical Technology Co., Ltd. | Multi-arm targeted anti-cancer conjugate |
| US12329382B2 (en) | 2017-09-01 | 2025-06-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Thixotropic biocompatible gel for live cell observation in cell computed tomography |
| JP7285828B2 (ja) | 2017-09-05 | 2023-06-02 | トルク セラピューティクス， インコーポレイテッド | 治療用タンパク質組成物ならびにその作製および使用方法 |
| CN107854693B (zh) * | 2017-11-14 | 2020-07-14 | 高瑞耀业(北京)科技有限公司 | 整合素受体靶向的抗癌偶联物 |
| WO2019096096A1 (zh) * | 2017-11-14 | 2019-05-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂靶向偶联物 |
| CN109776787B (zh) * | 2017-11-14 | 2021-08-03 | 博瑞生物医药（苏州）股份有限公司 | 多臂靶向偶联物 |
| CN111526891B (zh) * | 2017-12-27 | 2023-10-20 | 三洋化成工业株式会社 | 药品原料药用原料或药品用添加物和使用了它们的药品原料药或药品 |
| MX2020007306A (es) * | 2018-01-12 | 2020-09-25 | Prolynx Llc | Tratamiento sinergico de cancer. |
| US11458094B2 (en) * | 2018-01-31 | 2022-10-04 | Regents Of The University Of Minnesota | Compositions and methods for treating pulmonary edema or lung inflammation |
| CN110256533B (zh) * | 2018-03-12 | 2022-05-10 | 博瑞生物医药（苏州）股份有限公司 | 一种高纯度的多臂抗癌偶联物的提取方法 |
| CN110577552A (zh) * | 2018-06-08 | 2019-12-17 | 遵义医学院 | 喜树碱-甘氨酸-5,6-双脱氢去甲斑蝥素结合物及其应用 |
| JP7546552B2 (ja) | 2018-09-17 | 2024-09-06 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | ポリマーベースの高分子プロドラッグ |
| CN111603567B (zh) | 2019-02-22 | 2024-12-27 | 赣江新区博瑞创新医药有限公司 | Cd44靶向多臂偶联物 |
| JP2022545402A (ja) * | 2019-08-15 | 2022-10-27 | ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク | 腫瘍関連エキソソームの免疫抑制をブロックするホスファチジルセリン結合分子 |
| CA3177377A1 (en) | 2020-03-27 | 2021-09-30 | Regents Of The University Of Minnesota | Compositions and methods for treating pulmonary edema or lung inflammation |
| CN114705801B (zh) * | 2022-01-24 | 2024-02-27 | 中国食品药品检定研究院(国家药品监督管理局医疗器械标准管理中心、中国药品检验总所) | 一种利福霉素类药物中亚硝酸根离子的测定方法 |
| WO2025053315A1 (ko) * | 2023-09-08 | 2025-03-13 | 파로스젠 주식회사 | 항암제 프로드러그 컨쥬게이트의 제조에서 팔라듐의 회수 및 제거 방법 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1222261B (de) * | 1963-04-20 | 1966-08-04 | Bayer Ag | Verfahren zur Herstellung von Polyaethern durch Polymerisation von Alkylenoxyden |
| GB1157753A (en) * | 1966-06-24 | 1969-07-09 | Bp Chem Int Ltd | Improvements in or relating to Synthetic Lubricants |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US5399728A (en) * | 1993-04-05 | 1995-03-21 | Arco Chemical Technology, L.P. | Process for the preparation of highly esterified alkoxylated polyol compositions |
| GB9704126D0 (en) * | 1997-02-27 | 1997-04-16 | Ici Plc | Surfactants |
| DE19817676A1 (de) * | 1998-04-21 | 1999-10-28 | Bayer Ag | Verfahren zur aufarbeitungsfreien Herstellung langkettiger Polyetherpolyole |
| WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| DE19937114C2 (de) * | 1999-08-06 | 2003-06-18 | Bayer Ag | Verfahren zur Herstellung von Polyetherpolyolen |
| US6762325B2 (en) | 2001-05-16 | 2004-07-13 | Nippon Shokubai Co., Ltd. | Method for production of alkoxylated compound |
| SE523934C2 (sv) * | 2001-09-24 | 2004-06-01 | Perstorp Specialty Chem Ab | Förfarande för av alkoxylering av di-, tri och polyalkoholer |
| US6608076B1 (en) * | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
| WO2004032862A2 (en) * | 2002-10-09 | 2004-04-22 | Insert Therapeutics, Inc. | Cyclodextrin-based materials, compositions and uses related thereto |
| US20050043215A1 (en) * | 2003-02-19 | 2005-02-24 | Tamara Minko | Complex drug delivery composition and method for treating cancer |
| TR201907313T4 (tr) * | 2003-05-23 | 2019-06-21 | Nektar Therapeutics | İki PEG zinciri içeren PEG türevleri. |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| ES2629696T3 (es) * | 2003-09-17 | 2017-08-14 | Nektar Therapeutics | Profármacos poliméricos multibrazo |
| JP4805911B2 (ja) * | 2004-03-15 | 2011-11-02 | ネクター セラピューティクス | Ｈｉｖ侵入阻害剤のポリマー系組成物及び複合体 |
| ES2534853T3 (es) * | 2004-10-01 | 2015-04-29 | Kabushiki Kaisha Yakult Honsha | Sal de adición de ácido de irinotecán |
| EP1885403B1 (en) | 2005-04-12 | 2013-05-08 | Nektar Therapeutics | Poly(ethyleneglycol) conjugates of Lysostaphin |
| EP2412744B1 (en) * | 2005-07-18 | 2014-01-22 | Nektar Therapeutics | Method for preparing branched functionalised polymers using branched polyol cores |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| IE20060565A1 (en) * | 2006-07-28 | 2008-02-06 | Eurand Pharmaceuticals Ltd | Drug delivery system based on regioselectively amidated hyaluronic acid |
| JP5105166B2 (ja) * | 2007-12-19 | 2012-12-19 | 公益財団法人野口研究所 | ポリエーテルの製造方法 |
| ME03396B (me) | 2009-11-18 | 2020-01-20 | Nektar Therapeutics | Oblici kisele soli konjugata polimer-lek |
-
2010
- 2010-11-18 ME MEP-2019-185A patent/ME03396B/me unknown
- 2010-11-18 CA CA2780779A patent/CA2780779C/en active Active
- 2010-11-18 ES ES10782159T patent/ES2723026T3/es active Active
- 2010-11-18 EA EA201200751A patent/EA023503B1/ru unknown
- 2010-11-18 LT LTEP10782159.7T patent/LT2501413T/lt unknown
- 2010-11-18 CA CA2780645A patent/CA2780645C/en active Active
- 2010-11-18 EP EP10782159.7A patent/EP2501413B1/en active Active
- 2010-11-18 SI SI201031891T patent/SI2501413T1/sl unknown
- 2010-11-18 MX MX2012005794A patent/MX338134B/es active IP Right Grant
- 2010-11-18 KR KR1020127015273A patent/KR101779229B1/ko active Active
- 2010-11-18 BR BR112012011943-5A patent/BR112012011943A2/pt not_active Application Discontinuation
- 2010-11-18 DK DK10782159.7T patent/DK2501413T3/da active
- 2010-11-18 RS RS20190781A patent/RS58901B1/sr unknown
- 2010-11-18 MX MX2012005795A patent/MX337393B/es active IP Right Grant
- 2010-11-18 WO PCT/US2010/057292 patent/WO2011063158A1/en not_active Ceased
- 2010-11-18 US US13/510,587 patent/US9226969B2/en active Active
- 2010-11-18 JP JP2012540065A patent/JP5901073B2/ja active Active
- 2010-11-18 CA CA3063465A patent/CA3063465C/en active Active
- 2010-11-18 HR HRP20191138TT patent/HRP20191138T1/hr unknown
- 2010-11-18 EA EA201290342A patent/EA024533B1/ru unknown
- 2010-11-18 US US13/510,555 patent/US20130143909A1/en not_active Abandoned
- 2010-11-18 PL PL10782159T patent/PL2501413T3/pl unknown
- 2010-11-18 KR KR1020127015272A patent/KR101790804B1/ko active Active
- 2010-11-18 CN CN201080061613.6A patent/CN102711837B/zh active Active
- 2010-11-18 CN CN201080061609.XA patent/CN102711836B/zh active Active
- 2010-11-18 EP EP10781794.2A patent/EP2501412B1/en active Active
- 2010-11-18 WO PCT/US2010/057289 patent/WO2011063156A2/en not_active Ceased
- 2010-11-18 JP JP2012540064A patent/JP5951496B2/ja active Active
- 2010-11-18 PT PT10782159T patent/PT2501413T/pt unknown
- 2010-11-18 SM SM20190294T patent/SMT201900294T1/it unknown
- 2010-11-18 ES ES10781794.2T patent/ES2623677T3/es active Active
- 2010-11-18 EP EP19152138.4A patent/EP3498754A1/en active Pending
- 2010-11-18 AU AU2010321882A patent/AU2010321882B2/en active Active
- 2010-11-18 HU HUE10782159A patent/HUE043689T2/hu unknown
- 2010-11-18 BR BR112012011947A patent/BR112012011947B8/pt active IP Right Grant
-
2012
- 2012-05-17 IL IL219866A patent/IL219866A/en active IP Right Grant
- 2012-05-17 IL IL219865A patent/IL219865A/en active IP Right Grant
-
2014
- 2014-05-21 US US14/284,067 patent/US9320808B2/en active Active
-
2015
- 2015-10-07 JP JP2015199074A patent/JP2016006127A/ja active Pending
-
2016
- 2016-03-21 US US15/075,750 patent/US20160200867A1/en not_active Abandoned
-
2019
- 2019-06-18 CY CY20191100623T patent/CY1121700T1/el unknown
-
2020
- 2020-10-02 US US17/062,457 patent/US11834553B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013511540A5 (https=) | ||
| JP2013511539A5 (https=) | ||
| US11224595B2 (en) | Subcutaneous delivery of poly(oxazoline) polymer conjugates | |
| EP1792927B1 (en) | Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient | |
| JP5901073B2 (ja) | マルチアームポリマー−薬物コンジュゲートの塩形態 | |
| CN111344018B (zh) | 聚乙二醇化卡非佐米化合物的稳定的组合物 | |
| JP7551749B2 (ja) | ポリエチレングリコール複合薬、ならびにその調製方法およびその使用 | |
| EA028413B1 (ru) | Фармацевтические композиции | |
| JP2011519833A5 (https=) | ||
| CN103705942A (zh) | 抗微生物组合物 | |
| TWI861015B (zh) | 包含抗原肽-佐劑核苷酸結合物之免疫誘導劑及包含其之醫藥組成物 | |
| JP2012515195A5 (https=) | ||
| WO2018192550A1 (zh) | 多臂靶向抗癌偶联物 | |
| TW201036639A (en) | Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates | |
| CN112584869A (zh) | 用于治疗癌症的方法的缀合物 | |
| TW200838561A (en) | Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof | |
| JP6253008B2 (ja) | 高分子化ホウ素化合物及びその使用 | |
| CN111789964B (zh) | 具有还原响应性的硒类聚合物前药胶束、制备方法和应用 | |
| WO2009142328A1 (ja) | カンプトテシン高分子誘導体及びその用途 | |
| US20170079928A1 (en) | Copolymers of formula (i) and uses | |
| WO2024233985A1 (en) | Biodegradable oligomers and polymers for oligonucleotide and gene delivery | |
| CN112543664A (zh) | 树枝状体配制品 | |
| US11952461B2 (en) | Siloxy polyethylene glycol and derivatives thereof | |
| US20200325274A1 (en) | Tertiary alkoxy polyethylene glycol and derivatives thereof | |
| WO2024124148A1 (en) | Lipid compounds and methods of making and use thereof |